Journal of Neurosurgery published Phase 2 study results on Dec. 18, 2015.
Here are seven takeaways:
1. DBS involves a neurostimulator delivering electrical signals to certain areas of the brain to regulate abnormal signals.
2. DBS is already approved to treat Parkinson’s disease and essential tumor.
3. Francisco Ponce, MD, director of Barrow Center for Neuromodulation, thinks there may be potential for DBS in the realm of Alzheimer’s. The study focuses on the fornix, because of the memory pathway.
4. The Advance Trial utilizes a Functional Neuromodulation device. The study involves 42 patients with mild Alzheimer’s.
5. The study demonstrated no adverse device effects and no neurological deficits or instances of mortality.
6. The researchers concluded DBS surgery focusing on the fornix is safe for patients.
7. The next phase of the study focuses on the DBS’ efficacy and long-term safety.
More articles on spine:
Mountain Spine Care adds Dr. Glenn Trent: 3 key notes
Drs. Andrew Manista, Jonathan Tuttle & more: 10 spine, neurosurgeons in the headlines this week
5 results from AMA survey on opioid abuse
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
